Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

FOUND: 3 | Mind Blowing Facts

Company's new wearable device will help diabetics eat right, lose weight

SAN DIEGO — San Diego's Dexcom, a maker of continuous glucose monitors, laid out plans for a new wearable device coming in 2024 for people with Type 2 diabetes who don't need insulin — a move that could help bring wearable health monitors closer to the mainstream.

Tribune News Service

Tory election chief's own firm admits Britain's 'economic misery made worse' by ministers

Millionaire banker Stephen Massey has taken over the running of the Conservative Party's local election campaign. His City firm warned Britain is facing 'insipid growth' under this government

Daily Mirror

Benzinga's Top Ratings Upgrades, Downgrades For November 1, 2022

Upgrades

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Meta Platforms To $200? These Analysts Slash Price Targets On Meta Following Q3 Results

Meta Platforms, Inc. (NASDAQ: META) reported worse-than-expected Q3 EPS and issued Q4 revenue guidance with a midpoint below estimates. The company also guided FY23 expenses of $96 billion to $101 billion. Meta Platforms shares dropped 22.1% to $101.20 on Thursday.

Benzinga

This Is What Whales Are Betting On Beyond Meat

Someone with a lot of money to spend has taken a bullish stance on Beyond Meat (NASDAQ:BYND). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

This Is What Whales Are Betting On Beyond Meat

A whale with a lot of money to spend has taken a noticeably bearish stance on Beyond Meat. Looking at options history for Beyond Meat (NASDAQ:BYND) we detected 11 strange trades.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For October 11, 2022

Upgrades

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Benzinga's Top Ratings Upgrades, Downgrades For September 30, 2022

Upgrades

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2022

Upgrades For Berkshire Hathaway Inc (NYSE:BRK), Edward Jones upgraded the previous rating of Hold to Buy. Berkshire Hathaway earned $6312.49 in the second quarter, compared to $4399.91 in the year-ago quarter.

Benzinga

Ethereum Is 'Blue Chip Blockchain,' Could See Significant Value Boost: Canaccord Analysts

Cryptocurrency Ethereum (CRYPTO: ETH) and the smart contract ecosystem were sized up by Canaccord Genuity in a new note.

Benzinga

Salesforce Faces Price Target Cuts On Guidance Cut, Shares Slide

Salesforce Inc (NYSE: CRM) reported upbeat results for its second quarter, but lowered its annual projections.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022

Benzinga

This MicroStrategy Analyst Is Slashing Their Price Target After $1B Loss, Michael Saylor Steps Down

MicroStrategy (NYSE: MSTR) recently reported a net loss of more than $1 billion in the second quarter compared with a loss of about $299.3 million in the same period last year.

Benzinga

Tesla Whale Trades For July 29

Someone with a lot of money to spend has taken a bearish stance on Tesla (NASDAQ:TSLA). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Check Out What Whales Are Doing With Tesla

Benzinga

Here's Why Accolade Shares Are Trading Higher Today

Needham analyst Ryan MacDonald reiterated a Buy rating on Accolade, Inc (NASDAQ:ACCD) with a price target of $12. Following a problematic 4QF22, he noted that Accolade bounced back nicely in 1QF23 as the company beat management's initial outlook for FY23 revenue and adjusted EBITDA. While early in the selling season, ACCD won more new business in 1QF23 than…

Benzinga

Canaccord Genuity Maintains Buy Rating for InMode: Here's What You Need To Know

Canaccord Genuity has decided to maintain its Buy rating of InMode (NASDAQ:INMD) and lower its price target from $50.00 to $40.00. Shares of InMode are trading down 2.15% over the last 24 hours, at $22.76 per share. A move to $40.00 would account for a 75.75% increase from the current…

Benzinga

Crypto Analyst Still Bullish On Bitcoin Miners, Names 4 Top Stock Picks

Plummeting cryptocurrency prices have made life difficult for Bitcoin (CRYPTO: BTC) miners in 2022, but Canaccord Genuity analyst Joseph Vafi said Monday that he maintains his bullish long-term outlook for crypto miners Argo Blockchain ADR (NASDAQ:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

This Snowflake Analyst Is Turning Bullish On Innovation, Valuation

Snowflake Inc’s (NYSE: SNOW) analyst day and customer conference highlighted innovations that could lead to higher consumption and better monetization, according to Canaccord Genuity.

Benzinga

Why Snowflake Stock Is Heating Up Today

Snowflake Inc (NYSE: SNOW) shares are trading higher Wednesday following bullish analyst coverage from Canaccord Genuity.

Benzinga

These 18 Clinical Trials Could Shape The Future Of The Psychedelics Industry

In the nascent industry of medical psychedelics, drug development is the name of the game. This subset of biotech, poised to become a $100 billion industry according to Canaccord Genuity, bases its success on the regulation and approval of scheduled psychoactive substances for mental health and other health indications.

Benzinga

Read How Analysts Reacted To MongoDB Post Q1 Earnings Beat

Analysts appreciated MongoDB, Inc's (NASDAQ:MDB) Q1 beat but cut the price target to reflect macro headwinds. Needham analyst Mike Cikos maintained MongoDB with a Buy rating and lowered the price target from $362 to $310. The price target change reflected the declines in the broader stock market. Cikos acknowledged MongoDB's strong 1QF23 feat outperforming guidance and expectations.…

Insider UK

Adam & Co strengthened by parent's latest acquisition

Deal sees the Edinburgh-based team double in size

Benzinga

Canaccord Genuity Maintains Buy Rating for Evolent Health: Here's What You Need To Know

Canaccord Genuity has decided to maintain its Buy rating of Evolent Health (NYSE:EVH) and raise its price target from $40.00 to $45.00. Shares of Evolent Health are trading down 2.43% over the last 24 hours, at $27.84 per share.

Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For May 6, 2022

Upgrades For Coupang Inc (NYSE:CPNG), JP Morgan upgraded the previous rating of Neutral to Overweight. The stock has a 52-week-high of $46.00 and a 52-week-low of $11.91. At the end of the last trading period, Coupang closed at $11.99.

1 2 3 4

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.